CU23980B1 - Formulación liposomal y proceso para la preparación del mismo - Google Patents

Formulación liposomal y proceso para la preparación del mismo

Info

Publication number
CU23980B1
CU23980B1 CU2009000114A CU20090114A CU23980B1 CU 23980 B1 CU23980 B1 CU 23980B1 CU 2009000114 A CU2009000114 A CU 2009000114A CU 20090114 A CU20090114 A CU 20090114A CU 23980 B1 CU23980 B1 CU 23980B1
Authority
CU
Cuba
Prior art keywords
preparation
same
liposomal formulation
liposome
phase transition
Prior art date
Application number
CU2009000114A
Other languages
English (en)
Other versions
CU20090114A7 (es
Inventor
Chunlei Li
Jinxu Wang
Caixia Wang
Yanhui Li
Dongmin Shen
Wenmin Guo
Li Zhang
Lan Zhang
Original Assignee
Cspc Zhongqi Pharmaceutical Technology Shaijiazhuang Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cspc Zhongqi Pharmaceutical Technology Shaijiazhuang Co filed Critical Cspc Zhongqi Pharmaceutical Technology Shaijiazhuang Co
Publication of CU20090114A7 publication Critical patent/CU20090114A7/es
Publication of CU23980B1 publication Critical patent/CU23980B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con una preparación farmacéutica liposómica que contiene un medicamento iónico multivalente, con un proceso para la elaboración de la preparación farmacéutica liposómica y con el uso de las mismas en el tratamiento de enfermedades, en donde el liposoma tiene un tamaño aproximado de 30 a 80 nm y la bicapa fosfolipídica tiene un fosfolípido con una temperatura de transición de fase Tm mayor a la temperatura corporal, de manera tal que la temperatura de transición de fase del liposoma es mayor a la temperatura corporal.
CU2009000114A 2006-12-29 2009-06-29 Formulación liposomal y proceso para la preparación del mismo CU23980B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006101023398A CN101209243B (zh) 2006-12-29 2006-12-29 一种脂质体药物及其制备方法
PCT/CN2007/071403 WO2008080367A1 (en) 2006-12-29 2007-12-29 Liposome formulation and process for preparation thereof

Publications (2)

Publication Number Publication Date
CU20090114A7 CU20090114A7 (es) 2011-02-24
CU23980B1 true CU23980B1 (es) 2014-01-29

Family

ID=39588170

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2009000114A CU23980B1 (es) 2006-12-29 2009-06-29 Formulación liposomal y proceso para la preparación del mismo

Country Status (15)

Country Link
US (2) US20110002977A1 (es)
EP (1) EP2123260B1 (es)
JP (3) JP2010514708A (es)
KR (1) KR101126629B1 (es)
CN (1) CN101209243B (es)
AU (1) AU2007341803B2 (es)
BR (1) BRPI0720733A2 (es)
CA (1) CA2673924C (es)
CO (1) CO6190601A2 (es)
CU (1) CU23980B1 (es)
ES (1) ES2401526T3 (es)
MX (1) MX2009007089A (es)
MY (1) MY150670A (es)
RU (1) RU2494729C2 (es)
WO (1) WO2008080367A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2008141230A1 (en) 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
US20110223675A1 (en) * 2008-11-20 2011-09-15 Terumo Kabushiki Kaisha Drug release means from liposomes and method for evaluating releasability
US9968583B2 (en) 2009-03-30 2018-05-15 Eisai R & D Management Co., Ltd. Method of manufacture of liposome composition
AU2014200717B2 (en) * 2009-03-30 2016-02-25 Eisai R&D Management Co., Ltd. Liposome composition
DK2415470T3 (en) * 2009-03-30 2016-09-19 Eisai R&D Man Co Ltd liposome
CN101897667B (zh) * 2009-05-26 2012-01-25 石药集团中奇制药技术（石家庄）有限公司 一种盐酸多柔比星脂质体注射剂及其制备工艺
CN105126179B (zh) * 2009-07-14 2018-09-25 波利皮得有限公司 持续释放药物载体组合物
CN102038640B (zh) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 一种含有胆固醇的peg修饰物的脂质体药物及其制备方法
EP2568961A2 (en) * 2010-05-10 2013-03-20 Michael A. Schmidt Therapeutic liposomes and methods for producing and using the same
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US12097269B2 (en) * 2010-10-27 2024-09-24 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
EP2770980A4 (en) 2011-10-25 2015-11-04 Univ British Columbia LOW SIZE LIPID NANOPARTICLES AND METHODS THEREOF
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
EP3470061A1 (en) * 2012-11-20 2019-04-17 Spectrum Pharmaceuticals, Inc. Improved method for the preparation of a dosage of liposome encapsulated vincristine for therapeutic use
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
WO2014172045A1 (en) 2013-03-15 2014-10-23 The University Of British Columbia Lipid nanoparticles for transfection and related methods
US10220095B2 (en) 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
KR101503492B1 (ko) * 2013-07-03 2015-03-19 전북대학교산학협력단 지질 및 리소좀 효소를 포함하는 리포좀 캡슐 및 그 제조방법
LT3138555T (lt) 2014-04-30 2021-03-25 Fujifilm Corporation Liposomų kompozicija ir jų gamybos būdas
EP3138557B1 (en) * 2014-04-30 2023-06-07 FUJIFILM Corporation Liposome composition and method for producing same
US12226529B2 (en) 2015-08-25 2025-02-18 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
US11279749B2 (en) 2015-09-11 2022-03-22 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
RU2768178C2 (ru) 2015-11-02 2022-03-23 Фуджифилм Корпорэйшн Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
CN110381922A (zh) * 2017-01-18 2019-10-25 淡马锡生命科学研究院有限公司 超稳定脂质体增加对有丝分裂细胞的靶向作用
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
CN108721644B (zh) * 2018-06-05 2021-06-08 常州金远药业制造有限公司 一种紫杉烷类药物脂质体制备方法
WO2019244978A1 (ja) 2018-06-20 2019-12-26 富士フイルム株式会社 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
CN110711178A (zh) * 2018-07-11 2020-01-21 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
KR20220140805A (ko) * 2020-02-10 2022-10-18 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 유방암 치료를 위한 미토산트론 염산염 리포솜의 용도
WO2021180184A1 (zh) * 2020-03-12 2021-09-16 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
WO2021208842A1 (zh) * 2020-04-13 2021-10-21 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
CN113876711A (zh) * 2020-07-01 2022-01-04 江苏长泰药业有限公司 一种盐酸阿霉素脂质体的制备工艺
US20230293454A1 (en) * 2020-08-07 2023-09-21 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Use of mitoxantrone hydrochloride liposome and pegaspargase
KR20230058137A (ko) * 2020-08-27 2023-05-02 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 미토산트론 염산염 리포솜 및 시클로포스파미드, 빈크리스틴, 프레드니손의 용도
CN116600788B (zh) * 2020-12-15 2025-12-26 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
JP7752698B2 (ja) 2021-04-16 2025-10-10 石薬集団中奇制薬技術（石家庄）有限公司 ミトキサントロン塩酸塩リポソームの応用
JP7682303B2 (ja) * 2021-05-28 2025-05-23 石薬集団中奇制薬技術（石家庄）有限公司 進行固形腫瘍を治療する薬物の製造のためのミトキサントロン塩酸塩リポソームの用途
CN115770288A (zh) * 2021-09-07 2023-03-10 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体、硼替佐米和地塞米松治疗多发性骨髓瘤的用途
CN117940164A (zh) * 2022-04-26 2024-04-26 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途
WO2024017293A1 (zh) 2022-07-20 2024-01-25 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
US20260021131A1 (en) 2022-08-29 2026-01-22 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Use of mitoxantrone liposome in combination with capecitabine in treating nasopharyngeal carcinoma
PL444722A1 (pl) * 2023-05-03 2024-11-04 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym
WO2024245378A1 (zh) 2023-06-02 2024-12-05 石药集团中奇制药技术（石家庄）有限公司 包含米托蒽醌脂质体和阿糖胞苷的药物组合物治疗急性髓系白血病的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5169635A (en) * 1989-11-17 1992-12-08 Fuji Photo Film Co., Ltd. Photoresponsive liposome
EP0804925A1 (en) * 1994-03-28 1997-11-05 Daiichi Pharmaceutical Co., Ltd. Liposome with increased retention volume
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP0825852B1 (en) * 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
AU751439B2 (en) * 1997-09-16 2002-08-15 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6355268B1 (en) * 1998-09-16 2002-03-12 Alza Corporation Liposome-entrapped topoisomerase inhibitors
HK1047046B (zh) * 1999-07-16 2005-06-03 阿尔萨公司 抗冻/融损害的脂质体组合物
ES2186484B1 (es) * 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
IL155291A0 (en) 2000-10-16 2003-11-23 Neopharm Inc Liposomal formulation of mitoxantrone
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US7179484B2 (en) * 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
CN101229127B (zh) * 2002-11-26 2012-10-10 吉里德科学公司 脂质体制剂
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
US7288396B2 (en) * 2003-09-11 2007-10-30 Kosan Biosciences Incorporated Biosynthetic gene cluster for leptomycins
RU2258530C1 (ru) * 2004-04-27 2005-08-20 Генкин Дмитрий Дмитриевич Способ профилактики и коррекции изменений кожи
KR101223366B1 (ko) * 2004-05-03 2013-01-16 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
CN1242740C (zh) * 2004-08-05 2006-02-22 常州太平洋药物研究所有限公司 米托蒽醌或盐酸米托蒽醌脂质体注射剂及其制备工艺
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006298844A (ja) * 2005-04-21 2006-11-02 Konica Minolta Medical & Graphic Inc リポソーム内に医薬化合物を内包するリポソーム含有製剤
WO2006116458A2 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhances immunostimulatory activity
WO2007028154A2 (en) * 2005-09-02 2007-03-08 Northwestern University Encapsulated arsenic drugs
HUE029994T2 (en) * 2005-12-08 2017-04-28 Insmed Inc Lipid-based compositions of antiinfectives for treating pulmonary infections
US7703945B2 (en) 2006-06-27 2010-04-27 Cree, Inc. Efficient emitting LED package and method for efficiently emitting light
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
DK2415470T3 (en) * 2009-03-30 2016-09-19 Eisai R&D Man Co Ltd liposome
JP5480867B2 (ja) * 2011-10-07 2014-04-23 住友ゴム工業株式会社 空気入りタイヤ

Also Published As

Publication number Publication date
EP2123260B1 (en) 2013-02-20
ES2401526T3 (es) 2013-04-22
US20160235671A1 (en) 2016-08-18
MX2009007089A (es) 2009-10-08
KR101126629B1 (ko) 2012-03-26
AU2007341803A1 (en) 2008-07-10
BRPI0720733A2 (pt) 2014-01-07
CA2673924A1 (en) 2008-07-10
EP2123260A1 (en) 2009-11-25
MY150670A (en) 2014-02-28
WO2008080367A1 (en) 2008-07-10
RU2494729C2 (ru) 2013-10-10
JP2013177397A (ja) 2013-09-09
CO6190601A2 (es) 2010-08-19
CN101209243A (zh) 2008-07-02
CN101209243B (zh) 2010-12-08
AU2007341803A2 (en) 2009-09-03
KR20090094043A (ko) 2009-09-02
CA2673924C (en) 2013-10-01
HK1133398A1 (en) 2010-03-26
AU2007341803B2 (en) 2011-08-11
JP2010514708A (ja) 2010-05-06
RU2009126983A (ru) 2011-02-10
US20110002977A1 (en) 2011-01-06
EP2123260A4 (en) 2010-03-17
CU20090114A7 (es) 2011-02-24
US10028913B2 (en) 2018-07-24
JP6187961B2 (ja) 2017-08-30
JP2015180652A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
CU23980B1 (es) Formulación liposomal y proceso para la preparación del mismo
AR077764A1 (es) Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos
CO6430467A2 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas
BRPI0608297A2 (pt) composições de lipossomos
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR112014010467A2 (pt) pistão para um cartucho a ser cheio com um medicamento, cartucho para ser utilizado com um dispositivo de administração de fármaco e método de fabricação de um pistão
ECSP13013010A (es) Preparación de gadobutrol de alta pureza
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
MX2016006896A (es) Microcapsulas de lipidos que comprenden preferiblemente una substancia activa lipofilica y composicion que las contiene, su metodo de preparacion y su uso en dermatolgia y cosmetica.
CR20120605A (es) Formulación tópica para un inhibidor de jak
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
BR112012003283A8 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
CL2011000814A1 (es) Uso de auna mikacina liposomal que comprende un lipido y amikacina para preparar un medicamento util para el tratamiento de un desorden pulmonar en un paciente.
MX362882B (es) Composición de liposomas para usarse en diálisis peritoneal.
PT2459153E (pt) Composição farmacêutica ou cosmética ou dietética tendo o efeito de favorecer a pigmentação capilar
ES2879383T3 (es) Fórmulas mixtas
MX2009011900A (es) Curacion de herida diabetica.
AR080970A1 (es) Uso de una composicion que contiene fosfolipidos para eliminar acumulaciones por lipolisis subcutanea
PE20120956A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
EP4403220A3 (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
Bowe et al. Therapeutic update: acne
IL217519A (en) Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders
BRPI1009003A2 (pt) "método para expressão recombinante de um ccn1 humano, uso de um ccn1 humano, anticorpo contra ccn1 humano, uso de um anticorpo contra ccn1 humano, método para a fabricação de um medicamento para o tratamento de doenças e composição farmacêutica"

Legal Events

Date Code Title Description
FG Grant of patent